Market Overview

Benzinga's Top #PreMarket Gainers

Share:
Related ICPT
Intercept Pharma Shares Higher Following New Buy Rating, $465 Target From UBS
Biotech Investors: Nomura Says To Watch These Dates
Next Week In Biotech: Earnings Deluge - From GSK And Achillion To Intercept And Vivus (Seeking Alpha)
Related SGMO
Biogen Or Bluebird: Which Will Lead In SCD?
Gene Therapy Stocks Take Beating On Bad News For Celladon
Biogen or Bluebird: Which Will Lead in SCD? (GuruFocus)

Intercept Pharmaceuticals (NASDAQ: ICPT) shares jumped 119.43% to $159.00 in pre-market trading after the company reported that the FLINT trial of obeticholic acid has been stopped early and the NASH primary endpoint has been met.

Sangamo Biosciences (NASDAQ: SGMO) shares gained 13.64% to $15.50 in the pre-market after the company and Biogen Idec (NASDAQ: BIIB) announced the global collaboration to develop treatments for hemoglobinopathies.

Sequenom (NASDAQ: SQNM) surged 10.16% to $2.71 in the pre-market session after the company announced the issuance of European patent for novel methods of detecting fetal aneuploidy.

Macy's (NYSE: M) soared 7.06% to $55.50 in the pre-market trading after the company announced its plans to lower 2,500 jobs and shut five Macy's stores. It also reported a 3.6% rise in its comparable sales in November and December. The retailer also issued upbeat outlook for 2014. BMO Capital upgraded the stock from Market Perform to Outperform and lifted the target price from $53 to $70.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers

 

Related Articles (BIIB + ICPT)

Around the Web, We're Loving...